Sutro Biopharma Inc (STRO) 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Form S-8 - Securities to be offered to employees in employee benefit plans

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company...

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro...

Form 8-K - Current report

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

- Expects to deliver three Investigational New Drug (IND) applications in next three years based on...